Abstract: BA-1049 (R) and its active metabolite are disclosed. Also disclosed are pharmaceutical formulations containing BA-1049 (R) or its active metabolite.
Type:
Grant
Filed:
July 21, 2021
Date of Patent:
November 14, 2023
Assignee:
BioAxone BioSciences, Inc.
Inventors:
Kenneth M. Rosen, Matthew D. Abbinanti, Joerg Ruschel, Lisa McKerracher, Lisa Bond Moritz
Abstract: Provided are methods of treating a cerebral cavernous malformation (CCM) and methods of treating cerebral aneurysm in a mammal with certain rho kinase inhibitors.
Type:
Grant
Filed:
December 7, 2020
Date of Patent:
July 18, 2023
Assignee:
BioAxone BioSciences, Inc.
Inventors:
Kenneth M. Rosen, Steven Wayne Riesinger, Lisa McKerracher, Lisa Bond Moritz
Abstract: The present invention provides, among other things, improved therapeutic compositions comprising a C3 fusion protein and methods of making and using the same. In particular, the present invention provides improved methods for the treatment of spinal cord injury and other CNS trauma and/or facilitate axon growth or other tissue repair.
Type:
Grant
Filed:
May 30, 2018
Date of Patent:
May 10, 2022
Assignee:
BioAxone BioSciences, Inc.
Inventors:
Ricardo Borjas, Mark Fleming, Mei Huang, Mayur Jain, Tapan Sanghvi, Kumkum Saxena, Amaris Torres-Delgado, Ping Yin, Lisa McKerracher, Elizabeth Ryu
Abstract: BA-1049 (R) and its active metabolite are disclosed. Also disclosed are pharmaceutical formulations containing BA-1049 (R) or its active metabolite.
Type:
Application
Filed:
July 21, 2021
Publication date:
March 24, 2022
Applicant:
BioAxone BioSciences, Inc.
Inventors:
Kenneth M. ROSEN, Matthew D. ABBINANTI, Joerg RUSCHEL, Lisa MCKERRACHER, Lisa BOND MORITZ
Abstract: BA-1049 (R) and its active metabolite are disclosed. Also disclosed are pharmaceutical formulations containing BA-1049 (R) or its active metabolite.
Type:
Grant
Filed:
January 6, 2020
Date of Patent:
December 14, 2021
Assignee:
BioAxone BioSciences, Inc.
Inventors:
Kenneth M. Rosen, Matthew D. Abbinanti, Joerg Ruschel, Lisa McKerracher, Lisa Bond Moritz
Abstract: Self-delivering PTEN RNA and methods of reducing PTEN expression are provided herein. Also provided are methods of treating spinal cord injury (SCI) and other neurotrauma with PTEN sdRNA.
Type:
Grant
Filed:
July 27, 2017
Date of Patent:
August 24, 2021
Assignee:
BioAxone BioSciences, Inc.
Inventors:
Joerg Ruschel, Lisa McKerracher, Emily Niederst, Kenneth M. Rosen
Abstract: Provided are methods of treating a cerebral cavernous malformation (CCM) and methods of treating cerebral aneurysm in a mammal with certain rho kinase inhibitors.
Type:
Grant
Filed:
December 10, 2018
Date of Patent:
December 8, 2020
Assignee:
BioAxone BioSciences, Inc.
Inventors:
Kenneth M. Rosen, Steven Wayne Riesinger, Lisa McKerracher, Lisa Bond Moritz
Abstract: Disclosed are therapeutic compositions including BA-1076 and/or BA-2057, methods of their use in the treatment of ophthalmological disorders. The therapeutic compositions may further include an IOP-lowering prostaglandin. The methods may further include administration of an IOP-lowering prostaglandin.
Type:
Grant
Filed:
July 11, 2018
Date of Patent:
January 21, 2020
Assignee:
BioAxone BioSciences, Inc.
Inventors:
Joerg Ruschel, Matthew D. Abbinanti, Kenneth M. Rosen, Lisa McKerracher
Abstract: BA-1049 (R) and its active metabolite are disclosed. Also disclosed are pharmaceutical formulations containing BA-1049 (R) or its active metabolite.
Type:
Grant
Filed:
May 24, 2018
Date of Patent:
January 7, 2020
Assignee:
BioAxone BioSciences, Inc.
Inventors:
Kenneth M. Rosen, Matthew D. Abbinanti, Joerg Ruschel, Lisa Mckerracher, Lisa Bond Moritz
Abstract: Provided are methods of treating a cerebral cavernous malformation (CCM) and methods of treating cerebral aneurysm in a mammal with certain rho kinase inhibitors.
Type:
Grant
Filed:
May 9, 2017
Date of Patent:
December 11, 2018
Assignee:
BioAxone BioSciences, Inc.
Inventors:
Kenneth M. Rosen, Steven Wayne Riesinger, Lisa McKerracher, Lisa Bond Moritz
Abstract: The disclosure provides rho kinase inhibitor BA-1049(R), an hydroxy metabolite of BA-1049(R), and adipate salts and deuterated forms thereof, useful for treating CNS disorders and injuries.
Type:
Grant
Filed:
May 9, 2017
Date of Patent:
October 23, 2018
Assignee:
BioAxone BioSciences, Inc.
Inventors:
Kenneth M. Rosen, Matthew D. Abbinanti, Joerg Ruschel, Lisa Mckerracher, Lisa Bond Moritz
Abstract: Provided are methods of treating a cerebral cavernous malformation (CCM) and methods of treating cerebral aneurysm in a mammal with certain Rho kinase inhibitors.